



neurogen 2004

Options

» Home » Publications » U.S. newspapers and newswires » U.S. newswires » PR Newswire » Jan - Mar 2004 » January 13,

Save

Export

E-mail

Print

Cite

Permalink

Neurogen Reports Phase IIa Clinical Trial Results for Oral Asthma Drug.

[PR Newswire](#)January 13, 2004 | [Copyright](#)

Like

0

Share

Neurogen Corporation , a small molecule drug discovery and development company, today announced top-line results from its Phase IIa clinical trial for asthma using NGD 2000-1, the first oral C5a antagonist to be tested in humans for the treatment of asthma. In this exploratory trial, designed to evaluate the potential benefit of blocking the C5a receptor in patients with mild to moderate asthma, NGD 2000-1 did not demonstrate a therapeutic benefit with respect to predetermined endpoints.

William H. Koster, PhD, President and CEO of **Neurogen** said, "We're disappointed that blocking the C5a receptor did not appear to provide a therapeutic benefit in the asthma study. ...